Incyte Corporation (INCY) & Trius Therapeutics (TSRX) Head to Head Comparison
Incyte Corporation (NASDAQ: INCY) and Trius Therapeutics (NASDAQ:TSRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitabiliy, institutional ownership, earnings, valuation, risk and analyst recommendations.
Valuation & Earnings
This table compares Incyte Corporation and Trius Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Incyte Corporation||$1.23 billion||20.74||$35.53 million||($0.54)||-230.70|
Incyte Corporation has higher revenue and earnings than Trius Therapeutics.
This table compares Incyte Corporation and Trius Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for Incyte Corporation and Trius Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Incyte Corporation presently has a consensus price target of $143.33, indicating a potential upside of 15.05%. Given Incyte Corporation’s higher probable upside, research analysts clearly believe Incyte Corporation is more favorable than Trius Therapeutics.
Insider & Institutional Ownership
92.8% of Incyte Corporation shares are held by institutional investors. 13.7% of Incyte Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Incyte Corporation beats Trius Therapeutics on 5 of the 8 factors compared between the two stocks.
Incyte Corporation Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
Trius Therapeutics Company Profile
Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.